Decision Due Next Month On Job-Creating EU SPC Manufacturing Waiver

A decision is due to be taken next month on whether to go ahead with a proposal for an EU supplementary protection certificate manufacturing waiver that could create thousands of new manufacturing jobs in the generics and biosimilars industry and increase competition on the European market.

EU Brussels — A European Commission decision on SPC manufacturing waivers is due soon

The European Commission is due to decide next month whether to go ahead with legislation that would allow generics and biosimilar companies in Europe to manufacture stocks of their versions of medicines that are still protected by EU supplementary protection certificates (SPCs), provided the products are destined for markets outside the EU.

Marc Alexander Mahl, president of the generic and biosimilars industry body, Medicines for Europe, said there was a need to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Mifepristone: Judge Orders US FDA To Rethink Need For REMS Restrictions

Nov 05 2025

• By Sue Sutter

A federal judge in Hawaii ruled the FDA failed to consider statutory factors relevant to the REMS and provide a “reasoned explanation” for its restrictive treatment of the drug, but remand could result in an agency determination that more extensive restrictions are needed.

EU Biotech Act: Careful Drafting Needed To Protect SMEs From ‘Over-Regulation’

Nov 04 2025

• By Eliza Slawther

In this second of a two-part series, Clifford Chance partner and life sciences legal expert Gunnar Sachs explains how the upcoming EU Biotech Act could place extra strain on SMEs due to overlap with other regulations and how to mitigate this through careful planning.

How The EU Biotech Act Could ‘Level The Playing Field’ For SMEs

Oct 30 2025

• By Eliza Slawther

While industry awaits specific details on the EU Biotech Act, Clifford Chance partner and life sciences legal expert Gunnar Sachs explains the key aims of the new legislation and discusses the potential benefits for biotech firms.

‘Sufficiently Large To Act As An Incentive’: Teva’s EU Provigil Antitrust Fine Upheld Again

Oct 29 2025

• By Dean Rudge

The EU’s top court has rejected Teva and Cephalon’s final appeal, ruling that their 2005 settlement to delay a generic version of modafinil was inherently anticompetitive and upheld a €60.5m fine.

‘Why We Would Do It Again’ – Gilead & Roche On Pioneering Global Initiative For Manufacturing Change

Nov 12 2025

Gilead and Roche reflect on their experiences with a global initiative that delivered aligned regulatory decisions through joint hybrid inspections and synchronized review of post-approval changes.

Novel Alzheimer’s Drug Blarcamesine Scheduled For High-Stakes EMA Oral Explanation

Nov 12 2025

• By Neena Brizmohun

The EMA has scheduled oral explanation meetings this week for Anavex’s blarcamesine and three other products that are nearing the end of the regulatory review cycle. These meetings usually represent the final chance for sponsors to persuade the agency that their product merits approval.

The British Pharmacopoeia: Setting standards that are trusted worldwide

In this exclusive article with Peter Crowley, Secretary and Scientific Director of the BP Commission, you’ll discover how the BP is preparing for its landmark 2026 edition while strengthening its influence as a global bridge between science, regulation, and industry.